- $211.79bn
- $238.63bn
- $64.17bn
- 94
- 70
- 51
- 84
Annual balance sheet for Merck & Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8,062 | 8,096 | 13,192 | 7,093 | 13,689 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 7,851 | 9,230 | 10,110 | 11,072 | 11,119 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 27,764 | 30,266 | 35,722 | 32,168 | 38,782 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 17,986 | 19,279 | 22,768 | 24,488 | 25,149 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 91,588 | 105,694 | 109,160 | 106,675 | 117,106 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 27,327 | 23,872 | 24,239 | 25,694 | 28,420 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 66,271 | 67,510 | 63,169 | 69,094 | 70,793 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 25,317 | 38,184 | 45,991 | 37,581 | 46,313 |
| Total Liabilities & Shareholders' Equity | 91,588 | 105,694 | 109,160 | 106,675 | 117,106 |
| Total Common Shares Outstanding |